A 68-year-old man from Delhi presents with progressive lower urinary tract symptoms for 8 months. He reports nocturia 4–5 times per night, hesitancy, weak urinary stream, and incomplete emptying. Digital rectal examination reveals a smooth, firm, symmetrically enlarged prostate without nodules. Post-void residual (PVR) by ultrasound is 120 mL. Serum PSA is 2.8 ng/mL. Uroflowmetry shows peak flow of 8 mL/s. He has no fever, no dysuria, and urinalysis is normal. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient has **symptomatic benign prostatic hyperplasia (BPH)** with moderate outlet obstruction: - **LUTS score**: Nocturia (4–5×), hesitancy, weak stream, incomplete emptying — all obstructive symptoms - **Objective findings**: Peak flow 8 mL/s (normal >15 mL/s), PVR 120 mL (mild–moderate), smooth enlarged prostate - **PSA normal**: Rules out malignancy - **No acute retention or recurrent UTI**: No indication for immediate surgical intervention ## Management Algorithm for Symptomatic BPH ```mermaid flowchart TD A[Symptomatic BPH confirmed]:::outcome --> B{Acute retention or recurrent UTI?}:::decision B -->|Yes| C[TURP or other surgical intervention]:::action B -->|No| D{Moderate-severe symptoms + obstruction?}:::decision D -->|Yes| E[Alpha-blocker ± 5-ARI]:::action D -->|No| F[Watchful waiting + lifestyle modification]:::action E --> G{Response at 4-6 weeks?}:::decision G -->|Yes| H[Continue medical therapy]:::outcome G -->|No| I[Add 5-ARI or consider TURP]:::action ``` ## Why Alpha-Blocker First? **Key Point:** Alpha-1 adrenergic antagonists (tamsulosin, alfuzosin, doxazosin) are **first-line medical therapy** for symptomatic BPH because they: 1. Relax smooth muscle in the prostate capsule and bladder neck (dynamic obstruction) 2. Provide **rapid symptom relief** within 1–2 weeks 3. Have **no impact on prostate size** (unlike 5-ARI) 4. Are well-tolerated with minimal side effects **High-Yield:** Tamsulosin 0.4 mg daily is the **preferred alpha-blocker** in BPH due to uroselective action (fewer systemic side effects than non-selective agents). ## Why Not Other Options? | Option | Why Not Appropriate | |--------|---------------------| | **5-ARI monotherapy** | Slower onset (3–6 months), reserved for large prostates (>30–40 g) or as add-on therapy; this patient has no indication for monotherapy | | **Immediate TURP** | Reserved for refractory cases, acute retention, recurrent UTI, or failure of medical therapy; not first-line | | **Urodynamic studies** | Not indicated in uncomplicated BPH; reserved for complex cases (neurogenic LUTS, prior pelvic surgery, atypical presentation) | **Clinical Pearl:** Response to alpha-blockers is assessed at 4–6 weeks. If inadequate, a 5-alpha reductase inhibitor (finasteride, dutasteride) can be added for combination therapy, especially if prostate is large (>40 g) or PSA elevated. ## Treatment Timeline **High-Yield:** The classic BPH management sequence is: 1. **Watchful waiting** (mild symptoms) 2. **Alpha-blocker** (moderate symptoms, first-line medical) 3. **Alpha-blocker + 5-ARI** (large prostate, inadequate response) 4. **TURP or other surgery** (refractory, complications, patient preference) [cite:Harrison 21e Ch 297]